The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Venetoclax plus azacitidine in treatment-naïve and R/R MDS
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, discusses the results of two Phase Ib dose-escalation trials (NCT02942290; NCT02966782) of combined venetoclax and azacitidine, in treatment-naïve high-risk myelodysplastic syndrome (MDS) and relapsed/refractory (R/R) high-risk MDS, respectively. Venetoclax, a BCL-2 inhibitor, has shown synergy with hypomethylating agents in preclinical studies of MDS. The trial in treatment-naïve patients showed the combination to be tolerable and induce high response rates that were durable. Similarly, venetoclax and azacitidine produced encouraging rates of complete remission in relapsed/refractory patients and had a manageable safety profile. Both trials are ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting fees: Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol-Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead
